Pharmaceutical Companies
-
Aptar Pharma partners with Macquarie University on dry powder inhaled biologics
The collaboration comes as pharmaceutical developers explore alternative delivery routes for biologic medicines, which can present formulation and administration challenges because of their molecular size and complexity.
-
Boehringer Ingelheim sells China biologics CDMO unit to Shanghai RAAS
Shanghai-based Raas disclosed the proposed acquisition in a financial filing, stating that it plans to acquire a 100% stake in Boehringer Ingelheim Biopharmaceuticals in China.
-
Vertex expands partnership with MNGHA to advance gene therapy care in Saudi Arabia
The announcement was made at the Riyadh Global Medical Biotechnology Summit (RGMBS), building on a collaboration established after Saudi Arabia’s first gene therapy infusion in 2024.
-
Novartis licenses preclinical radioligand asset from China’s BoomRay in US$900M global deal
The agreement brings together BoomRay’s expertise in radioligand therapy development and Novartis’ global capabilities in radiopharmaceutical research and commercialisation.
-
Boehringer Ingelheim partners with Envisagenics to identify precision cancer targets in 2026
The collaboration will assess selected targets for several therapeutic approaches, including antibody-drug conjugates (ADCs), multispecific antibodies and T cell engagers (TcEs).
-
Roche expands breast cancer Initiatives across Africa to improve survival by 2030
Currently, about five in 10 women diagnosed with breast cancer in Africa survive for at least five years after diagnosis.
-
Telix inks US$1.67B acquisition deal for Germany’s ITM Isotope Technologies
Following completion of the acquisition, ITM shareholders are expected to hold 23.7% of Telix, while existing Telix shareholders will retain 76.3%.
-
Sandoz expands biosimilar pipeline with mAbxience deal for haemophilia A treatment
The agreement covers licensing, development, manufacturing and commercialisation of the candidate, which is currently in the early stages of development.
-
WuXi XDC licenses ADC technology to Ona Therapeutics
The arrangement gives Ona Therapeutics access to WuXi XDC’s capabilities across ADC development and manufacturing as it advances the candidate towards clinical development.
-
Novadip Biosciences secures US$12M to advance regenerative therapy
Novadip will use the proceeds to advance NVD003, its lead autologous cell-based therapy, through late-stage clinical development and regulatory preparation.